La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
National Medical Care Croissance future
Future contrôle des critères 2/6
National Medical Care devrait augmenter ses bénéfices et son chiffre d'affaires de 8.6% et de 12.4% par an respectivement. Le BPA devrait croître de de 9.5% par an. Le rendement des capitaux propres devrait être 18.5% dans 3 ans.
Informations clés
8.9%
Taux de croissance des bénéfices
9.7%
Taux de croissance du BPA
Healthcare croissance des bénéfices | 14.8% |
Taux de croissance des recettes | 12.5% |
Rendement futur des capitaux propres | 18.6% |
Couverture par les analystes | Good |
Dernière mise à jour | 23 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
Analysts Are Updating Their National Medical Care Company (TADAWUL:4005) Estimates After Its Second-Quarter Results
Aug 06Getting In Cheap On National Medical Care Company (TADAWUL:4005) Is Unlikely
Jul 26National Medical Care Company's (TADAWUL:4005) Shares May Have Run Too Fast Too Soon
Apr 05We Think National Medical Care's (TADAWUL:4005) Robust Earnings Are Conservative
Mar 14National Medical Care (TADAWUL:4005) Is Very Good At Capital Allocation
Mar 13Some Confidence Is Lacking In National Medical Care Company's (TADAWUL:4005) P/E
Dec 27Returns On Capital Are Showing Encouraging Signs At National Medical Care (TADAWUL:4005)
Dec 05We Like These Underlying Return On Capital Trends At National Medical Care (TADAWUL:4005)
Aug 07Is National Medical Care Company (TADAWUL:4005) Worth ر.س107 Based On Its Intrinsic Value?
May 29Investors Will Want National Medical Care's (TADAWUL:4005) Growth In ROCE To Persist
May 08Investors Will Want National Medical Care's (TADAWUL:4005) Growth In ROCE To Persist
Dec 19A Look At The Fair Value Of National Medical Care Company (TADAWUL:4005)
Oct 19National Medical Care (TADAWUL:4005) Is Doing The Right Things To Multiply Its Share Price
Aug 15National Medical Care's (TADAWUL:4005) Returns On Capital Are Heading Higher
May 13Earnings Update: National Medical Care Company (TADAWUL:4005) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Mar 03A Look At The Fair Value Of National Medical Care Company (TADAWUL:4005)
Feb 10Returns At National Medical Care (TADAWUL:4005) Appear To Be Weighed Down
Nov 10Returns On Capital At National Medical Care (TADAWUL:4005) Have Hit The Brakes
Jul 02Estimating The Intrinsic Value Of National Medical Care Company (TADAWUL:4005)
Apr 14Is National Medical Care Company (TADAWUL:4005) A Risky Dividend Stock?
Mar 25Will National Medical Care (TADAWUL:4005) Multiply In Value Going Forward?
Feb 23Update: National Medical Care (TADAWUL:4005) Stock Gained 25% In The Last Five Years
Feb 09National Medical Care Company's (TADAWUL:4005) Stock Been Rising But Financials Look Weak: Should Shareholders Be Worried?
Jan 27Calculating The Fair Value Of National Medical Care Company (TADAWUL:4005)
Jan 14Is National Medical Care Company's (TADAWUL:4005) 3.8% Dividend Sustainable?
Dec 25Does National Medical Care's (TADAWUL:4005) Statutory Profit Adequately Reflect Its Underlying Profit?
Dec 10What Kind Of Shareholders Hold The Majority In National Medical Care Company's (TADAWUL:4005) Shares?
Nov 24Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 1,691 | 381 | 320 | 457 | 6 |
12/31/2025 | 1,501 | 347 | 204 | 395 | 7 |
12/31/2024 | 1,347 | 304 | 87 | 349 | 5 |
6/30/2024 | 1,171 | 288 | -134 | 88 | N/A |
3/31/2024 | 1,119 | 266 | 212 | 423 | N/A |
12/31/2023 | 1,082 | 241 | 412 | 467 | N/A |
9/30/2023 | 1,034 | 233 | 825 | 690 | N/A |
6/30/2023 | 997 | 202 | 670 | 531 | N/A |
3/31/2023 | 968 | 196 | 349 | 386 | N/A |
12/31/2022 | 918 | 170 | 185 | 217 | N/A |
9/30/2022 | 882 | 151 | -162 | 52 | N/A |
6/30/2022 | 857 | 142 | -126 | 86 | N/A |
3/31/2022 | 843 | 131 | 8 | 45 | N/A |
12/31/2021 | 845 | 136 | 56 | 94 | N/A |
9/30/2021 | 844 | 122 | 58 | 94 | N/A |
6/30/2021 | 845 | 105 | 15 | 49 | N/A |
3/31/2021 | 828 | 100 | 17 | 40 | N/A |
12/31/2020 | 809 | 97 | 88 | 107 | N/A |
9/30/2020 | 780 | 95 | 187 | 198 | N/A |
6/30/2020 | 740 | 95 | 216 | 225 | N/A |
3/31/2020 | 724 | 83 | 155 | 162 | N/A |
12/31/2019 | 708 | 80 | 152 | 162 | N/A |
9/30/2019 | 705 | 65 | 236 | 246 | N/A |
6/30/2019 | 707 | 60 | 245 | 259 | N/A |
3/31/2019 | 737 | 67 | 188 | 206 | N/A |
12/31/2018 | 764 | 62 | 299 | 318 | N/A |
9/30/2018 | 810 | 81 | 199 | 231 | N/A |
6/30/2018 | 842 | 96 | 194 | 236 | N/A |
3/31/2018 | 859 | 95 | N/A | 279 | N/A |
12/31/2017 | 855 | 85 | N/A | 113 | N/A |
9/30/2017 | 817 | -8 | N/A | -9 | N/A |
6/30/2017 | 806 | -7 | N/A | 70 | N/A |
3/31/2017 | 849 | 33 | N/A | 72 | N/A |
12/31/2016 | 901 | 50 | N/A | 103 | N/A |
9/30/2016 | 931 | 155 | N/A | 87 | N/A |
6/30/2016 | 945 | 153 | N/A | 63 | N/A |
3/31/2016 | 913 | 136 | N/A | 77 | N/A |
12/31/2015 | 879 | 131 | N/A | 51 | N/A |
9/30/2015 | 853 | 106 | N/A | 127 | N/A |
6/30/2015 | 820 | 102 | N/A | 80 | N/A |
3/31/2015 | 772 | 91 | N/A | 38 | N/A |
12/31/2014 | 734 | 95 | N/A | 71 | N/A |
9/30/2014 | 703 | 106 | N/A | 32 | N/A |
6/30/2014 | 660 | 103 | N/A | 15 | N/A |
3/31/2014 | 623 | 94 | N/A | 75 | N/A |
12/31/2013 | 586 | 92 | N/A | 79 | N/A |
9/30/2013 | 560 | 97 | N/A | 138 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 4005 ( 8.6% par an) est inférieure au taux d'épargne ( 14.5% ).
Bénéfices vs marché: Les bénéfices de 4005 ( 8.6% par an) devraient croître plus rapidement que le marché SA ( 6.7% par an).
Croissance élevée des bénéfices: Les bénéfices de 4005 devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de 4005 ( 12.4% par an) devrait croître plus rapidement que le marché SA ( 1.2% par an).
Croissance élevée des revenus: Le chiffre d'affaires de 4005 ( 12.4% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de 4005 devrait être faible dans 3 ans ( 18.5 %).